Is arterial hypertension an underlying factor in the increased serum Lp(a) levels in ESRD dialyzed patients?

Renal Failure

Volumn 24, Issue 5, 2002, Pages 631-638

  Fytili, Christina I ^a   Passadakis, Ploumis S ^b   Progia, Euaggelia G ^a   Kambouromiti, Georgia L ^b   Panopoulou, Maria I ^b   Sombolos, Kostas I ^a   Vargemezis, Vassilis A ^b  

^a G H 'G Papa nikolaou'   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Arterial hypertension; CAPD; Hemodialysis; Lipids; Lp(a)

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPOPROTEIN A; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS; ARTERIOSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; LIPOPROTEIN(A); MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RENAL DIALYSIS; TRIGLYCERIDES;

EID: 0036385613     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-120013967     Document Type: Article

References (9)

1. Raine, A.E.G.; Margreiter, R.; Brunner, F.P. et al. Report on Management of Renal Failure in Europe, XXII, 1991. Nephrol. Dial. Transplant. 1992, 7(Suppl. 2), 7-35.
2. USRDS 1994 Annual Report. Am. J. Kidney Dis. 1994, 24(Suppl. 2), S88-S95.
3. Attman, P.O.; Alaupovic, P.; Gustafson, A. Serum Apolipoprotein Profile of Patients with Chronic Renal Failure. Kidney Int. 1987, 32, 368-375.
4. Assmann, G.; Schulte, H.; von Eckardstein, A. Hypertriglyceridemia and Elevated Lipoprotein(a) are Risks Factors for Major Coronary Events in Middle-Aged Men. Am. J. Cardiol. 1996, 77, 1179-1184.
5. Dahlen, G.H. Lp(a) Lipoprotein in Cardiovascular Diseases. Atherosclerosis 1994, 108, 111-126.
6. Raitakari, O.T.; Adams, M.R.; Celermajer, D.S. Effect of Lp(a) on the Early Functional and Structural Changes of Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 1999, 19(4), 900-905.
7. Sechi, L.A.; Kronenberg, F.; De Carli, S.; Falleti, E.; Zingaro, L.; Catena, C.; Utermann, G.; Bartoli, E. Association of Serum Lipoprotein(a) Levels and Apolipoprotein(a) Size Polymorphism with Target-Organ Damage in Arterial Hypertension. JAMA 1997 Jun 4, 277(21), 1689-1695.
8. Gazzaruso, C.; Buscaglia, P.; Garzaniti, A.; Falcone, C.; Mariotti, S.; Savino, S.; Bonetti, G.; Finardi, G.; Geroldi, D. Association of Lipoprotein(a) Levels and Apolipoprotein(a) Phenotypes with Coronary Heart Disease in Patients with Essential Hypertension. J. Hypertens. 1997 Mar, 15(3), 227-235.
9. Wanner, C. Clinical Significance of Lipoprotein(a) Determination in Patients with Renal Disease. Journal of Nephrology 1996, 9(4), 157-159.